1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply
2022) In Alimentary Pharmacology and Therapeutics(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2021
-
Mark
Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers
(
- Contribution to journal › Article
- 2018
-
Mark
Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis
(
- Contribution to journal › Article
- 2017
-
Mark
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis
(
- Contribution to journal › Article
- 2013
-
Mark
Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life
(
- Contribution to journal › Article
- 2002
-
Mark
Leukocyte recruitment in hepatic injury: selectin-mediated leukocyte rolling is a prerequisite for CD18-dependent firm adhesion.
(
- Contribution to journal › Article
-
Mark
Protective effect of Linomide on TNF-alpha-induced hepatic injury.
(
- Contribution to journal › Article